Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

NCT04404660 is registered in ClinicalTrials.gov with Autolus Limited as lead sponsor.

NCT NCT04404660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Lead sponsor
Autolus Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 3, 2020
Completion date
June 30, 2029
Enrollment
153 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b cell acute lymphoblastic leukemia